Adjunct Faculty
CHEN Ling
Title:Principle Investigator
Subject:
Email:chen_ling@gibh.ac.cn
Address:
Study/Work Experience

2013now

Guangzhou Institute of Biomedicine and Health, CAS/State Key Lab of Respiratory Disease/Professor

20092012

GlaxoSmithKline/Sanofi Pasteur /Vice President of R&D

20042008

Guangzhou Institute of Biomedicine and Health, CAS/Founding Director General

Research Areas

Vaccine research, viral vector engineering, antibody discovery

Academic Performance

Dr. Chen is a Professor in Guangzhou Medical University, and a Distinguished Research Fellow in Guangzhou Institute of Biomedicine and Health (GIBH), where he was the founding Director General from 2004-2008. From 2013-2017, Dr. Chen also served as the Executive Deputy Director of the State Key Laboratory of Respiratory Disease. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He was selected as a CUSBEA Fellow in 1984 and went to USA to pursue a Ph.D. in Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.  From 1997-2001, Dr. Chen served as a Research Fellow and Senior Research Fellow at Merck Research Laboratories, where he was the key inventor on Merck’s MRK Ad5 based AIDS vaccine that entered phase IIb clinical trial worldwide. Dr. Chen served as Vice Presidents of R&D for GlaxoSmithKline in 2009-2011 and in 2012 as Vice President at Sanofi Pasteur. Dr. Chen has over 100 publications in infectious diseases, vaccine research, cancer research, and drug discovery in journals including Nature, Nature Communications, Journal of Clinical Investigation, Cancer Research, Blood, Journal of Virology, Journal of Immunology, Vaccine, etc.

Representative Papers

1. Liu X, Qu L, Ye X, Yi C, ……, Chen L*. Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein. NPJ Vaccines. 2018 Jul;3:29

2. Pan W, Xie H, Li X, ……, Huang J*, Chen L*. Patient-derived avian influenza A (H5N6) virus is highly pathogenic in mice but can be effectively treated by anti-influenza polyclonal antibodies. Emerging Microbes & Infections. 2018 Jun;7(1):107

3. Feng Y, Li C, ……, Feng L*, Chen L*. An adenovirus serotype 2 vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerging Microbes & Infections. 2018 Jun ;7(1):101

4. Ren Y, Li C, Feng L, ……, Sun C, Chen L*. Proton channel activity of influenza A virus matrix protein 2 contributes to autophagy arrest. Journal of Virology. 2015 Oct;90(1):591-598

5. Pan W, Dong Z, Feng L, ……, Chen L*. Visualizing influenza virus infection in living mice. Nature Communications. 2013 Sep; 9(4):2369